Introducing the BioStockInfo Catalyst Calendar — Free, and Built From Filings Only

Programming note. Before the next scanner issue, I want to introduce something I have been building quietly for the past few months, and to be open about where the newsletter goes from here.

What it is

The BioStockInfo Catalyst Calendar is now live at app.biostockinfo.com. It is free, it requires no sign-up, and it is in beta.

The idea is simple. Every US-listed drug developer tells you, in its own SEC filings, what it expects to happen next: a topline readout "in the second half of 2026", a PDUFA date, a conference presentation, an enrollment milestone. That information is public, but it is scattered across thousands of 8-Ks and 6-Ks, and most of us only see it when someone else has already traded on it. The calendar reads those press-release filings on EDGAR every night, extracts each forward-looking statement about an upcoming event, and puts it on a calendar in the company's own words, with a link to the filing it came from.

As of today it covers roughly 880 tickers and about 2,700 upcoming catalyst statements over the next year or so.

Each ticker page gives you, on one screen, what I usually spend the first twenty minutes of a deep dive assembling by hand: the pipeline as the company itself has described it in the last twelve months, the upcoming catalysts, the statement history of every program (so you can watch a timeline hold or slip from filing to filing), the company's own cash and runway sentences, financings pulled from filings, the recent press releases, and a dated cash and runway estimate of ours printed next to the company's own number. Price and chart data come from TradingView.

The one rule

We never guess a date. If a company said "September 2026", the calendar says September 2026. If it said "the second half of 2026", you see a six-month window, tagged as such. Most catalyst services turn vague guidance into a specific-looking date; I think the width of the window is itself information — it tells you how much control management actually has over its own timeline.

The same rule works in the other direction. If a company promised Q3 data and the quarter passes with nothing filed, the event does not quietly vanish. It stays on the calendar with a red "window closed, nothing filed since" tag, because a company that promised data files an 8-K when it arrives, and a silent quarter is a signal in itself. Regulatory dates are handled differently — an FDA decision is announced the same day whether or not an 8-K follows, so passed PDUFA dates are checked against the FDA's own database instead and shown as approved when the approval is on record.

What it is not

The calendar contains no recommendations, no price targets and no predictions. It does not tell you whether a trial will succeed; nobody can from the outside. A listing there is not an endorsement.

It is also not a live tool. The whole pipeline is automated and runs once a day, overnight. If a company files at 8 a.m., the calendar will not know until the next morning. Please do not use it to check whether something happened an hour ago — use it the way I do, as the place to glance at the latest filings, the pipeline, the catalysts and the basic fundamentals before deciding whether a name deserves a real deep dive.

On accuracy, honestly

I am not going to promise that it is perfectly accurate, because it will not be. Extraction is automated and filings are messy: a date can be misread, a program can be mislabelled, an old milestone can survive a filing that should have retired it. Anyone who has paid for a catalyst service knows the paid ones are full of errors and discrepancies too; I have written corrections in this newsletter because of them. The difference I can offer is that every row on our calendar links to the exact filing it was taken from, so you can check us in one click, and that it is free.

There are good paid catalyst services out there already, and most of them charge somewhere between $20 and $50 a month. I have no intention of competing with them, and I use some of them myself. What I can offer is a more accessible alternative for investors who look up biotech tickers regularly and would rather not add one more line to an already crowded stack of subscriptions — a free place to check a company's own words before deciding whether a name is worth a deeper look.

The beta label is meant literally. I am still working on the details and the depth — duplicate programs that should be merged, FDA designations that are extracted but not yet shown, the way multi-quarter windows are labelled — and things will change, and occasionally break, from week to week. If you find an error, I would much rather hear about it than have it stand. Email me at alex@biostockinfo.com or reach me through biostockinfo.com.

Where this is going

What I want to build, step by step, is a tool that makes due diligence on a biotech faster: one page per company where you can check, in a few minutes, the latest developments, the cash position, the pipeline, the upcoming catalysts, the latest news and the price trend, before you decide whether to spend an evening on the filings. Most of that is already on the ticker pages. The next addition I plan is a direct link to each company's latest corporate presentation, so that the slide deck management actually shows investors sits one click from the calendar that lists what management promised. Read together, the two tell you more than either does alone.

I also want the calendar to work properly on a phone. It already opens on mobile, but I intend to make it truly mobile-friendly, so you can check a company's catalysts and filings on the go — in the minute between reading a headline and deciding whether it matters — without waiting to get back to a desk.

Where the scanner newsletter goes next

The next generation of the BSI AI Catalyst Scanner is being built on this same data. Instead of relying on third-party catalyst calendars, the scanner will rank the upcoming month's catalysts from our own filings-based extraction, with the transparent scoring and the reading — the science, the competition, the balance sheet — that regular readers know. It is being tested internally now, and I am aiming to relaunch the scanner issue before the end of September. Names covered in the scanner are marked on their ticker pages in the app, together with what happened after we covered them, so the track record stays visible.

A note on subscriptions

Running this costs money. The filings ingestion, the language-model extraction, the market data and the hosting all have real bills, and until now they have come out of my own pocket. I am all in for free services, and I want to keep it that way, so here is what I plan to do.

I am introducing a single voluntary supporter tier for the newsletter, BioStockInfo Supporter, at $9 a month or $80 a year. Nothing is put behind it. Every article, the calendar and the app remain accessible to all subscribers regardless of subscription level, and there is no exclusive content. The tier exists for readers who find this useful and want to help cover the cost of keeping the system running and improving it. If a few dozen readers choose to, it pays for itself; if not, it stays free anyway and I will keep working on it as time allows. Either way I will report in the quarterly review how much of the running cost supporters are covering.

Thank you for reading and for the corrections and questions over the past year — they have shaped most of what is in the app. Go have a look: app.biostockinfo.com.

Disclaimer: The information on this site is provided for informational purposes only and should not be construed as financial, investment, legal, or professional advice, nor as a recommendation to buy or sell any security. Clinical-stage biotechnology involves substantial risk: most drug candidates fail in development, regulatory decisions are unpredictable, companies may dilute shareholders at any time, and small-cap stocks experience extreme price swings. Do your own research, understand the science, and consult a licensed financial advisor before investing. Past performance does not guarantee future results. BioStockInfo and its authors may hold positions in securities mentioned; positions are disclosed in the weekly reports.